Skip to content
Markets
SPY764.80▼ -1.07%QQQ709.16▼ -2.21%DIA527.55▼ -0.03%GLD370.91▼ -2.12%TLT81.34▲ +1.38%BABA102.47▼ -1.86%NIO3.33▼ -0.74%PDD79.54▲ +1.04%Realtime derived data
Octans ResearchOCTANS RESEARCHWaitlist
The columned Broad Street facade of the New York Stock Exchange building, hung with American flags.
Source: 颐园居, CC BY-SA 4.0, via Wikimedia Commons

Tenax Therapeutics 10% owner ADAR1 Capital Management LLC buys $1.5 million of shares

Open market purchase reported on Form 4, filed Oct 21, 2026.

Octans ResearchPublished

Snapshot

ADAR1 Capital Management LLC, a holder of more than 10% of the shares of Tenax Therapeutics (TENX), bought 922,849 shares in open market purchases between Oct 19, 2026 and Oct 21, 2026, about $1.5 million at an average price of $1.59 a share, according to a Form 4 filed with the SEC on Oct 21, 2026.

Coverage
Independent Research
Prepared by
Octans Research
Tickers
TENX
As of

Market Data

Latest prices for the companies covered in this article
Company1D %Price
($TENX)▲ +6.75%1.74

as of 12:03 ET · Realtime derived data

What We Know

The filing lists 3 open market purchase lines: • Oct 19, 2026: 336,528 shares at $1.51. • Oct 20, 2026: 254,342 shares at $1.60. • Oct 21, 2026: 331,979 shares at $1.66.

After the last purchase, the filing reports 7,447,000 shares held indirectly in that account.

Octans View

The purchases raised the holding reported in that account by about 14%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought. The filing is a joint filing with 1 related reporting person; the purchases are counted once.

Bear Case · Room for Disagreement

Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.

Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.

Chart

$TENX adjusted close, last 6 months $TENX adjusted close, last 6 months: series falling from 15.1 to 1.6 (−89.2%) from 2026-04-27 to 2026-10-21. Scale 0 to 20. 05101520 2026-04-272026-10-21 $TENX ADJUSTED CLOSE, LAST 6 MONTHS −89.2% 1.63
Source: Tiingo · As of 2026-10-21Indicative, not investment advice.

Sources

  1. [1]SEC EDGAR — Form 4 filed by ADAR1 Capital Management LLC for Tenax Therapeutics, Oct 21, 2026

These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.

$1.5M

ADAR1 Capital Management LLC, a holder of more than 10% of the shares of Tenax Therapeutics (TE… · Snapshot

Related coverage

More on $TENX

4 reports